SBRT for early-stage glottic larynx cancer-Initial clinical outcomes from a phase I clinical trial.
To confirm safety and feasibility of hypofractionated SBRT for early-stage glottic laryngeal cancer.Twenty consecutive patients with cTis-T2N0M0 carcinoma of glottic larynx were enrolled. Patients entered dose-fractionation cohorts of incrementally shorter bio-equivalent schedules starting with 50 G...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5333979?pdf=render |
| _version_ | 1818305544457289728 |
|---|---|
| author | David L Schwartz Alan Sosa Stephen G Chun Chiuxiong Ding Xian-Jin Xie Lucien A Nedzi Robert D Timmerman Baran D Sumer |
| author_facet | David L Schwartz Alan Sosa Stephen G Chun Chiuxiong Ding Xian-Jin Xie Lucien A Nedzi Robert D Timmerman Baran D Sumer |
| author_sort | David L Schwartz |
| collection | DOAJ |
| description | To confirm safety and feasibility of hypofractionated SBRT for early-stage glottic laryngeal cancer.Twenty consecutive patients with cTis-T2N0M0 carcinoma of glottic larynx were enrolled. Patients entered dose-fractionation cohorts of incrementally shorter bio-equivalent schedules starting with 50 Gy in 15 fractions (fx), followed by 45 Gy/10 fx and, finally, 42.5 Gy/5 fx. Maximum combined CTV-PTV expansion was limited to 5 mm. Patients were treated on a Model G5 Cyberknife (Accuray, Sunnyvale, CA).Median follow-up is 13.4 months (range: 5.6-24.6 months), with 12 patients followed for at least one year. Maximum acute toxicity consisted of grade 2 hoarseness and dysphagia. Maximum chronic toxicity was seen in one patient treated with 45 Gy/10 fx who continued to smoke >1 pack/day and ultimately required protective tracheostomy. At 1-year follow-up, estimated local disease free survival for the full cohort was 82%. Overall survival is 100% at last follow-up.We were able to reduce equipotent total fractions of SBRT from 15 to 5 without exceeding protocol-defined acute/subacute toxicity limits. With limited follow-up, disease control appears comparable to standard treatment. We continue to enroll to the 42.5 Gy/5 fx cohort and follow patients for late toxicity.ClinicalTrials.gov NCT01984502. |
| first_indexed | 2024-12-13T06:28:17Z |
| format | Article |
| id | doaj.art-945e0ede1ac74c2ba3a0e981f5b406d9 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T06:28:17Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-945e0ede1ac74c2ba3a0e981f5b406d92022-12-21T23:56:41ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01123e017205510.1371/journal.pone.0172055SBRT for early-stage glottic larynx cancer-Initial clinical outcomes from a phase I clinical trial.David L SchwartzAlan SosaStephen G ChunChiuxiong DingXian-Jin XieLucien A NedziRobert D TimmermanBaran D SumerTo confirm safety and feasibility of hypofractionated SBRT for early-stage glottic laryngeal cancer.Twenty consecutive patients with cTis-T2N0M0 carcinoma of glottic larynx were enrolled. Patients entered dose-fractionation cohorts of incrementally shorter bio-equivalent schedules starting with 50 Gy in 15 fractions (fx), followed by 45 Gy/10 fx and, finally, 42.5 Gy/5 fx. Maximum combined CTV-PTV expansion was limited to 5 mm. Patients were treated on a Model G5 Cyberknife (Accuray, Sunnyvale, CA).Median follow-up is 13.4 months (range: 5.6-24.6 months), with 12 patients followed for at least one year. Maximum acute toxicity consisted of grade 2 hoarseness and dysphagia. Maximum chronic toxicity was seen in one patient treated with 45 Gy/10 fx who continued to smoke >1 pack/day and ultimately required protective tracheostomy. At 1-year follow-up, estimated local disease free survival for the full cohort was 82%. Overall survival is 100% at last follow-up.We were able to reduce equipotent total fractions of SBRT from 15 to 5 without exceeding protocol-defined acute/subacute toxicity limits. With limited follow-up, disease control appears comparable to standard treatment. We continue to enroll to the 42.5 Gy/5 fx cohort and follow patients for late toxicity.ClinicalTrials.gov NCT01984502.http://europepmc.org/articles/PMC5333979?pdf=render |
| spellingShingle | David L Schwartz Alan Sosa Stephen G Chun Chiuxiong Ding Xian-Jin Xie Lucien A Nedzi Robert D Timmerman Baran D Sumer SBRT for early-stage glottic larynx cancer-Initial clinical outcomes from a phase I clinical trial. PLoS ONE |
| title | SBRT for early-stage glottic larynx cancer-Initial clinical outcomes from a phase I clinical trial. |
| title_full | SBRT for early-stage glottic larynx cancer-Initial clinical outcomes from a phase I clinical trial. |
| title_fullStr | SBRT for early-stage glottic larynx cancer-Initial clinical outcomes from a phase I clinical trial. |
| title_full_unstemmed | SBRT for early-stage glottic larynx cancer-Initial clinical outcomes from a phase I clinical trial. |
| title_short | SBRT for early-stage glottic larynx cancer-Initial clinical outcomes from a phase I clinical trial. |
| title_sort | sbrt for early stage glottic larynx cancer initial clinical outcomes from a phase i clinical trial |
| url | http://europepmc.org/articles/PMC5333979?pdf=render |
| work_keys_str_mv | AT davidlschwartz sbrtforearlystageglotticlarynxcancerinitialclinicaloutcomesfromaphaseiclinicaltrial AT alansosa sbrtforearlystageglotticlarynxcancerinitialclinicaloutcomesfromaphaseiclinicaltrial AT stephengchun sbrtforearlystageglotticlarynxcancerinitialclinicaloutcomesfromaphaseiclinicaltrial AT chiuxiongding sbrtforearlystageglotticlarynxcancerinitialclinicaloutcomesfromaphaseiclinicaltrial AT xianjinxie sbrtforearlystageglotticlarynxcancerinitialclinicaloutcomesfromaphaseiclinicaltrial AT lucienanedzi sbrtforearlystageglotticlarynxcancerinitialclinicaloutcomesfromaphaseiclinicaltrial AT robertdtimmerman sbrtforearlystageglotticlarynxcancerinitialclinicaloutcomesfromaphaseiclinicaltrial AT barandsumer sbrtforearlystageglotticlarynxcancerinitialclinicaloutcomesfromaphaseiclinicaltrial |